From: Update on leukotriene receptor antagonists in preschool children wheezing disorders
Author | Pros | Cons | |
---|---|---|---|
No difference: | |||
- in length of stay | |||
Amirav[47] | - in clinical severity score | ||
- in cytokine levels in nasal lavage fluid | |||
Bisgaard[48] | No differences in percentage symptom-free days | ||
No differences: | |||
Bronchiolitis and post bronchiolitis | Proesmans[49] | - of symptoms and disease-free days and nights | |
- of n° of exacerbations | |||
- of n° of unscheduled visits and need of inhaled steroids | |||
Higher percentage of symptom-free days and nights | |||
Bisgaard[50] | Reduced daytime cough | ||
Decreased exacerbations versus placebo | |||
Kim[51] | Reduced serum eosinophil-derived neurotoxin levels compared with initial levels | ||
Decreased cumulative recurrent wheezing episodes at 12 months versus placebo | |||
Harmanci[52] | Reduced oral steroids need | ||
Acute asthma | Decreased lung index scores and respiratory rate versus placebo | Hospitalization rates not significantly different | |
Robertson[33] | Reduced healthcare resource use, symptoms, time-off school/parent work | No effect on hospitalization rate, symptoms duration, β2 or steroids use | |
Bacharier[40] | No difference in symptom free-days, oral steroid, healthcare resource use |